Immutep Limited Overview
Pro stress-test →Immutep is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Strategic Profile
Pro stress-test →Immutep's diversified product portfolio harnesses LAG-3's ability to stimulate the immune response to fight cancer or modulate it to combat autoimmune diseases. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company is transitioning to Phase III operations with its lead candidate eftilagimod alfa progressing through pivotal trials.
Competitive Landscape
Pro stress-test →Immutep competes in the LAG-3 immunotherapy space against other checkpoint inhibitor developers. The company collaborates with major pharmaceutical players including Merck & Co., Inc., and Novartis, which both have competing LAG-3 programs, suggesting complementary rather than purely competitive relationships in this emerging therapeutic area.
Industry Context
Immutep Limited operates in Biotechnology - Immunotherapy.
Key facts
Founded: 1987 · Headquarters: Sydney, Australia · Revenue: $5.04M (2025) · Market cap: $582M